ICCM Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.249

Open

6.560

VWAP

6.36

Vol

9.03M

Mkt Cap

17.18M

Low

5.700

Amount

57.41M

EV/EBITDA(TTM)

--

Total Shares

2.81M

EV

8.53M

EV/OCF(TTM)

--

P/S(TTM)

112.38

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Show More

Events Timeline

(ET)

2026-06-22

10:00:00

Icecure Medical Ltd Trading Halted Due to Volatility Trading Pause

2026-06-17 (ET)

2026-06-17

08:30:00

IceCure Medical Reports 70% Increase in U.S. ProSense Install Base

2026-06-03 (ET)

2026-06-03

19:50:00

Icecure Medical Ltd Trading Halted, News Pending

2026-06-02 (ET)

2026-06-02

08:40:00

IceCure Medical to Implement 1-for-30 Reverse Split

2026-05-12 (ET)

2026-05-12

08:40:00

ProSense Q1 Revenue $911K, Below Consensus

2026-04-01 (ET)

2026-04-01

16:40:00

IceCure Medical Files to Sell 16M Ordinary Shares

News

PRnewswire

06-23PRnewswire

PinnedIceCure Medical Highlights Cryoablation Study in Top Surgical Journal

PRnewswire

06-17PRnewswire

IceCure Medical Completes Private Placement Financing

Newsfilter

06-17Newsfilter

IceCure Medical Completes Private Placement Financing

stocktwits

06-17stocktwits

IceCure Medical Receives FDA Authorization, Shares Surge 200%

Newsfilter

06-17Newsfilter

NeOnc Technologies Secures International Drug Authorization for NEO212

PRnewswire

06-17PRnewswire

IceCure Medical Sees Significant Growth Post FDA Approval

1 Analyst Rating

Wall Street analysts forecast ICCM stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Brookline

Buy

maintain

$73.50

AI Analysis

2026-06-17

Reason

Brookline

Price Target

$73.50

AI Analysis

2026-06-17

maintain

Buy

Reason

Brookline tells investors in a research note that IceCure Medical's disclosure of a 70% boost in the U.S. active commercial install base of ProSense for breast cancer cryoablation is "very encouraging," as evidence is rising in advance of reimbursement, confirming that there is a segment of the patient population that is willing to pay out-of-pocket to access the procedure. The firm, which has a Buy rating and $73.50 price target on the shares post-stock split, says business is "moving in the right direction."

Maxim

Maxim

Buy

maintain

$3 -> $1

2026-05-14

Reason

Maxim

Maxim

Price Target

$3 -> $1

2026-05-14

maintain

Buy

Reason

Maxim lowered the firm's price target on IceCure Medical to $1 from $3 and keeps a Buy rating on the shares. The company's Q1 loss per share was slightly wider than consensus, the analyst tells investors in a research note, adding that the firm is reducing its price target to reflect incremental share dilution.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ICCM

Unlock Now

Valuation Metrics

The current forward P/E ratio for Icecure Medical Ltd (ICCM.O) is 0.00, compared to its 5-year average forward P/E of -5.65. For a more detailed relative valuation and DCF analysis to assess Icecure Medical Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.65

Current PE

0.00

Overvalued PE

1.68

Undervalued PE

-12.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.04

Current EV/EBITDA

-0.12

Overvalued EV/EBITDA

0.09

Undervalued EV/EBITDA

-0.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

14.32

Current PS

1.21

Overvalued PS

29.71

Undervalued PS

-1.07

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

refine to volume over 500,000

Intellectia · 2764 candidates

Volume: >= 500,000

Ticker

Name

Market Cap$

Aditxt Inc

10.53K

Sleep Number Corp

8.99M

Hyperscale Data Inc

184.06M

GD Culture Group Ltd

6.39M

Azitra Inc

3.29M

Srx Health Solutions Inc

117.76M

what if I have $5000 to invest

Intellectia · 90 candidates

Region: USPrice: >= $-100.00Ema 20: >= -100News Driver: Positive

Ticker

Name

Market Cap$

Icecure Medical Ltd

17.96M

Uniqure NV

3.04B

Fathom Holdings Inc

36.39M

AstroNova Inc

219.65M

Allbirds Inc

48.26M

Euro Tech Holdings Company Ltd

11.64M

Whales Holding ICCM

Trading Trends

People Also Watch

Frequently Asked Questions

What is Icecure Medical Ltd (ICCM) stock price today?

The current price of ICCM is 6.12 USD — it has increased 3.2

What is Icecure Medical Ltd (ICCM)'s business?

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

What is the price predicton of ICCM Stock?

Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Icecure Medical Ltd (ICCM)'s revenue for the last quarter?

Icecure Medical Ltd revenue for the last quarter amounts to 911.00K USD, increased 25.66

What is Icecure Medical Ltd (ICCM)'s earnings per share (EPS) for the last quarter?

Icecure Medical Ltd. EPS for the last quarter amounts to -0.06 USD, decreased -0.00

How many employees does Icecure Medical Ltd (ICCM). have?

Icecure Medical Ltd (ICCM) has 67 emplpoyees as of June 24 2026.

What is Icecure Medical Ltd (ICCM) market cap?

Today ICCM has the market capitalization of 17.18M USD.